Upcoming event

The European School of Urology provides up-to-date information for urologists and residents worldwide.

E-courses are developed by urologists from all over Europe, supported by the e-learning specialists of the EAU and in line with the EAU Clinical Guidelines, delivering high standard, up-to-date courses.

EAU Education Online e-Platform is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide CME activity for medical specialists.

For infomation please visit EAU E-courses page.

The following E-courses are available at EAU website.

*NEW Advanced Prostate Cancer – Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

This course series Advanced Prostate Cancer gives clinicians a complete view on clinical aspects, diagnosis, and treatments of prostate cancer. This course is the fourth part of the course series.

Course 1: Basis of ADT (published in March 2020)
Course 2: Hormone-sensitive nmPCa
Course 3: Metastatic hormone-sensitive PCa (published in June 2020)
Course 4: Non-metastatic CRPC
Course 5: Metastatic CRPC

The development of this course has been supported by Jansen with a concession of an unrestricted educational grant.

Learning Objectives

  • Definition of Hormone sensitive nmPCa / nmPCa / MPCa / CRPC and classification
  • Information about diagnostic tools, how to combine them and the value of their results
  • Information on prognosis factors, predictive factors and patient stratification
  • Information about treatment options, how to combine them, their differences and side-effects, when to progress to the next treatment stage, and how to evaluate these
  • Information on sound clinical decision making for patients with nmPCa, MPCa, Metastatic CRPC, and nmCRPC
  • Evaluation of learners’ knowledge about treatment of nmPCa, MPCa, Metastatic CRPC, and nmCRPC and their ability to apply this knowledge in devising care pathways for patients

Chapters

Chapter 1: Definition and Occurrence
Chapter 2: Clarifying metastasis and progression
Chapter 3: Predicting outcomes: the role of PSA-DT
Chapter 4: Treatment

At a glance

  • Publication date: November 2020
  • Duration: 60-90 minutes approximately
  • CME: 1 European CME credits (ECMEC)

Advanced Prostate Cancer – Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

This course series Advanced Prostate Cancer gives clinicians a complete view on clinical aspects, diagnosis and treatments of prostate cancer. The five courses are:

Course 1: Basis of ADT
Course 2: Hormone-sensitive nmPCa
Course 3: Metastatic hormone-sensitive PCa
Course 4: Non-metastatic CRPC
Course 5: Metastatic CRPC

This course Metastatic Hormone-Sensitive Prostate Cancer is the third part of the course series.

The development of this course has been supported by Jansen with a concession of an unrestricted educational grant.

Learning Objectives

  • Definition of Hormone-sensitive nmPCa / nmPCa / MPCa / CRPC and classification
  • Information about diagnostic tools, how to combine them and the value of their results
  • Information on prognosis factors, predictive factors and patient stratification
  • Information about treatment options, how to combine them, their differences and side-effects, when to progress to the next treatment stage, and how to evaluate these
  • Information on sound clinical decision making for patients with nmPCa, MPCa, Metastatic CRPC, and nmCRPC
  • Evaluation of learners’ knowledge about treatment of nmPCa, MPCa, Metastatic CRPC, and nmCRPC and their ability to apply this knowledge in devising care pathways for patients

Chapters

  • Chapter 1: Definition and classification
  • Chapter 2: Clinical evaluation
  • Chapter 3: Treatment
  • Chapter 4: Follow-up and surveillance strategies

At a glance

  • Duration: 90 minutes per course approximately
  • CME: 1 European CME credits (ECMEC)

Advanced Prostate Cancer – Basis of Androgen Deprivation Therapy

This course series Advanced Prostate Cancer gives clinicians a complete view on clinical aspects, diagnosis and treatments of prostate cancer. The five courses are:

Course 1: Basis of ADT
Course 2: Hormone-sensitive nmPCa
Course 3: Metastatic hormone-sensitive PCa
Course 4: Non-metastatic CRPC
Course 5: Metastatic CRPC

This course Basis of Androgen Deprivation Therapy is the first part of the course series.

This course is supported by an independent educational grant from Janssen, the Pharmaceutical Companies of Johnson & Johnson.

Learning Objectives

  • Definition of Hormone-sensitive nmPCa / nmPCa / MPCa / CRPC and classification
  • Information about diagnostic tools, how to combine them and the value of their results
  • Information on prognosis factors, predictive factors and patient stratification
  • Information about treatment options, how to combine them, their differences and side-effects, when to progress to the next treatment stage, and how to evaluate these
  • Information on sound clinical decision making for patients with nmPCa, MPCa, Metastatic CRPC, and nmCRPC
  • Evaluation of learners’ knowledge about treatment of nmPCa, MPCa, Metastatic CRPC, and nmCRPC and their ability to apply this knowledge in devising care pathways for patients

Chapters

  • Chapter 1: Androgen Bio-synthesis
  • Chapter 2: Androgen Deprivation Therapy (ADT)
  • Chapter 3: Adverse Events and Side Effects

At a glance

  • Duration: 90 minutes per course approximately
  • CME: 1 European CME credits (ECMEC)

EAU Guidelines on Prostate Cancer

This course compiles the most recent clinical guidelines edited by the EAU on Prostate Cancer (PCa). The PCa guidelines course is divided into 4 learning modules.

Learning Objectives

  • Review the most updated EAU guidelines on Prostate Cancer
  • Learn how to make informed decisions in the treatment of Prostate Cancer Patients
  • Test your knowledge on the latest developments in Prostate Cancer according to the EAU Guidelines

At a glance

  • Duration: Approx. 180 minutes
  • CME: 3 European CME credits (ECMEC)